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ABSTRACT
Interleukins are important modulators of the immune response in the human body, which inevitably makes 
them participants in the intimate mechanisms of various diseases. Cardiovascular morbidity and mortal-
ity is high in the world as a whole, despite the ongoing primary and secondary prevention. Therefore their 
pathogenetic mechanisms are of significant research and clinical interest. A number of studies demonstrat-
ed changes in the interleukin status of patients with coronary heart disease, heart failure, some cardiomy-
opathies and rhythm conduction disorders. Significantly altered levels of basic for the immunity pro-in-
flammatory and anti-inflammatory cytokines were found. It was even proven, that some of them have pre-
dictive value for the manifestation of certain diseases. All this is a reason to allow interleukins to take part 
in the intimate mechanisms of cardiovascular diseases and consider the place of interleukin blockers in the 
treatment of these diseases.
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INTRODUCTION
Interleukins
Cytokines are signaling molecules, which by 
their nature are proteins or glycoproteins, secreted by 
specific cells of the immune system. Depending on 
their functions, type of secreting cells or purpose of 
action, cytokines are divided into interleukins, lym-
phokines and chemokines.
For the first time the term “interleukins” (ILs) 
was introduced in the medical literature in 1979 
(1). ILs represent a large group of secreted proteins, 
which play an essential role in the communication 
between leukocytes and that is where their name de-
rives from. They usually act in a paracrine or auto-
crine manner, binding with high affinity to specific 
for them receptors. Target cells respond to ILs stimu-
lation through new mRNA and protein synthesis (2). 
ILs perform growth, differentiation and activa-
tion functions, which to a significant degree regulate 
and determine the strength and duration of the im-
mune response (3). Therefore they have complex and 
substantially significant immunomodulatory as well 
as pro-inflammatory and anti-inflammatory effects 
(4).
It is well known that the fundamental response 
of innate immunity is inflammation, which protects 
the human body in case of infection and/or tissue 
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damage. Its manifestation, both on a local as well as 
system level, is determined precisely by the interleu-
kins – its important modulators.
Inflammation in cardiovascular diseases
A number of cardiovascular diseases are asso-
ciated with inflammation. It contributes significant-
ly to the pathophysiology of the coronary artery dis-
ease, given that the inflammatory cascade is at the 
base of the atherosclerotic process (5). Тhe impor-
tance of inflammation is also established in the man-
ifestation of heart failure (6), some cardiomyopathies 
(7, 8) and rhythm disorders (9). Given the regulatory 
and coordinating function that ILs exercise over the 
inflammation process, the interleukin balance repre-
sents a special research interest.
INTERLEUKINS AND CARDIOVAS-
CULAR DISEASES: THE FACTS
An immunohistochemical study found in-
creased levels of IL-1β protein in the wall of athero-
sclerotic coronary arteries, such as the rate of increase 
was proportional to atherosclerotic changes (10). In 
serum of patients with ischemic heart diseases, inter-
leukin levels are also elevated. IL-1β is the dominant 
circulating isoform of IL-1. It has an expressed pro-
inflammatory effect and once released can exert its 
effects both locally and systemically. The role of IL-
1β in the inflammatory response is a leading one and 
the enhanced values of the indicator are associated 
with presence of inflammation.
IL-6 also shows higher levels in patients with 
stable acute coronary syndrome compared to those 
measured in clinically stable angina pectoris (11). It, 
and its soluble receptor (IL-6R), are central regula-
tors of the inflammatory process. They activate in-
flammation by stimulating B-cell differentiation, T-
cell growth and induce the hepatic synthesis of CRP 
(12). In a study of Blankenberg et al. acute coronary 
events are associated with elevated levels of another 
interleukin, namely IL-18 (13).
In essence it is a pleiotropic pro-inflammato-
ry cytokine that plays a main role in the inflamma-
tory cascade. It stimulates the interferon-γ produc-
tion from T-lymphocytes and NK-cells, which are 
said to be the main cause for atherosclerotic plaque 
rupture. In the same study, statistical analysis shows 
that increased levels of the indicator are an indepen-
dent predictor of manifestation of ischemic heart dis-
ease (IHD) in a population of healthy, middle-aged 
European men. IHD is also characterized by ele-
vated levels of IL-8 and IL-12 (14). The main effec-
tor functions of IL-8 are associated with activation of 
neutrophils into the sites of infection or tissue dam-
age (15). Moreover, IL-8 has the ability to attract NK 
cells, T cells, basophils, and GM-CSF-primed or IL-
3-primed eosinophils. IL-12, like IL-8, exhibits pro-
inflammatory effects by inducing proliferation, cy-
totoxicity and cytokine production by NK-cells. Ac-
cording to a survey by Vaddi et al. patients with sta-
ble and unstable angina pectoris have elevated lev-
els of TNF-α and IFN-γ compared to controls with-
out coronary atherosclerosis (16). IFN-γ is produced 
by cells of the innate (NK cells, macrophages, etc.) 
and acquired (cytotoxic T lymphocytes, B cells and 
the like) immunity and together with TNF-α has 
expressed pro inflammatory properties. The estab-
lished in this study elevated levels are indicative of 
changes in the interleukin balance in patients with 
stable and unstable angina pectoris. A study by Eid 
et al. on atherosclerotic coronary arteries shows in-
creased production of other two cytokines IL-17 and 
IFN- γ (17). The obtained results are evidence of syn-
ergism of these cytokines and induction of pro-in-
flammatory response in smooth muscle cells of cor-
onary vessels. In their study Abdulkareem et al. es-
tablish impaired interleukin balance in patients with 
AMI and unstable angina pectoris, due to elevated 
levels of pro-inflammatory IL-8 and reduced values 
of anti-inflammatory IL-10 (18). Inflammation not 
only plays a fundamental role in the development of 
atherosclerosis and IHD, respectively, but is also re-
lated to the manifestation of early or delayed compli-
cations of the disease. For example, in patients with 
AMI and successful PTCA, serum concentrations of 
IL-10 are higher among patients who did not devel-
op heart failure as a complication of AMI (19). It is 
known that IL-10 has pronounced anti-inflammato-
ry properties and the ability to inhibit the synthesis 
of a number of pro-inflammatory cytokines. Its high 
values, established in the abovementioned study, 
suggest the protective effect of IL-10 on the myocard 
in ischemia, reperfusion, or both. In heart failure 
changes in IL-8 and TNF-α were observed. In a study 
by Nymo et al. in patients with chronic heart failure 
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(CHD) with adverse effect these indicators were sig-
nificantly elevated (20).
It is known that secretion of ILs is induced not 
only by micro-organisms, but also by mechanical 
stimuli such as pressure or volume overload. Inflam-
matory fibrosis is a distinctive feature of both myo-
carditis and CHF. IL-4 is a TH2 type anti-inflam-
matory cytokine that inhibits the pro-inflammato-
ry response of TNF-α, IL-1 and IL-6. Simultaneously 
it has expressed pro-fibrotic properties by activating 
the synthesis of collagen type I and type II from the 
fibroblasts and stimulates fibrosis (21).
A study conducted on patients with CHF and 
hypertensive cardiomyopathy found elevated levels 
of IL-4 and pro-inflammatory IL-6. Straight correla-
tion of these indicators with procollagen type III lev-
els gives the authors a reason to accept the presence 
of an activated inflammatory process that takes part 
in the collagen metabolism (22). In stable heart fail-
ure NYHA functional class II-IV Naito et al. estab-
lish an increase in two other pro-inflammatory fac-
tors, namely IL-18 and TNF-α (23). It is known that 
IL-18 alone stimulates the TH1-mediated immune 
response and thereby enhances the levels of two oth-
er pro-inflammatory essential factors – IL-6 and 
TNF-α.
IL-1 is considered as one of the most impor-
tant mediators of inflammatory responses, inducing 
a cascade of pro-inflammatory effector molecules. 
Studies show that its effect on the myocardium in-
cludes structural and functional changes in cardio-
myocytes such as myocardial hypertrophy, regula-
tion of MAP kinase pathway and induction of endo-
thelial growth factor, etc (24). Studies not only estab-
lish elevated cytokine values in chronic heart failure, 
but also prove its involvement in the regulation of the 
systemic inflammatory response in CHF (25).
Pathophysiological processes in cardiomyopa-
thies still continue to be a particular subject of in-
terest. Just as in many other diseases, inflammation 
has also found its place. For instance, it is established 
that radiation-induced cardiomyopathy is associat-
ed with elevated levels of the proinflammatory cyto-
kine IL-18 (26). Elevated levels of IL-6 are measured 
in peripartum cardiomyopathy (27). TNF-α and IL-6 
show an increase in idiopathic dilated cardiomyopa-
thy (28).
Interleukin changes are also observed in cardi-
ac arrhythmias. In experimental conditions the ex-
pression of ventricular tachycardia in acute myo-
cardial infarction is associated with an increase in 
TNF-α values (29). It is known that it has pleiotro-
pic biological effects associated with cell prolifera-
tion, differentiation, apoptosis and inflammatory re-
actions. Moreover, according to some studies it reg-
ulates the Ca2+ - flow and can induce electrical re-
modeling of the myocardium, which in the partic-
ular study could be the cause of the manifestation 
of the rhythm disorder. A study by Vasiletz et al. 
also found an increase of pro-inflammatory mark-
ers TNF-α and IL-6 in expression of ventricular ar-
rhythmias (30). Given the high incidence of atrial fi-
brillation (AF), the interleukin response in these pa-
tients is subject of numerous studies. According to 
Sid, the levels of IL-1β and TNF-α are significantly 
elevated in patients with permanent AF compared to 
surveyed controls without rhythm disorders, and the 
values  of TNF-α are predictive for the manifestation 
of the arrhythmia (31). The author believes that the 
results are not only indicative of the presence of in-
flammation in permanent AF, but are a major pre-
requisite to accept the participation of interleukins 
in the pathogenetic mechanisms of the disease. In 
postoperative AF the levels of pro-inflammatory in-
terleukins IL-6 and IL-8 are elevated (32). The levels 
of pro-inflammatory IL-2 have also been researched, 
although in single studies. Its low values are associ-
ated with reduced incidence of postoperative AF and 
increased success rate of pharmacological cardiover-
sion in recent-onset AF (33,34).
CONCLUSIONS
In conclusion we could say that in a number of 
cardiovascular diseases such IHD, CHF, some car-
diomyopathies and arrhythmias, disorders in the 
interleukin status of the body are observed. Signifi-
cantly altered are the levels of both pro-inflamma-
tory and anti-inflammatory ILs. Some of the stud-
ied cytokines such as IL-18, TNF-α, etc. have a pre-
dictive effect on the expression of a specific disease. 
The nature of the identified changes gives grounds to 
assume that interleukin response is not just an acci-
dental finding, but is most likely connected to the in-
timate mechanisms of diseases. This certainly rais-
es the question of how these research results can be 
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transferred into clinical practice. The confirmation 
of some ILs as prognostic indicators and their accep-
tance as potential therapeutic targets, would change 
completely the clinical approach in these diseases.
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